Pancreatic Cancer Research

ResearcherInsermActive in the last 2 years

Pierre Michel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6442-2566; OpenAlex author ID A5059592567. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
19
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: 2 papers

Papers 7

  1. Relative dose intensity of gemcitabine-nab-paclitaxel combination as second-line or more in locally advanced or metastatic pancreatic adenocarcinoma. Co-author DOI 10.1016/j.clinre.2025.102583↗
  2. Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PROD… Co-author DOI 10.1200/jco-24-01378↗
  3. Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer. Last author DOI 10.1093/oncolo/oyae079↗
  4. [Olaparib and pancreatic cancer: A challenging Lesson]. Last author DOI 10.1016/j.bulcan.2019.07.002↗
  5. Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODI… Co-author DOI 10.1186/s12885-018-4663-4↗
  6. Usefulness of circulating tumor cell detection in pancreatic adenocarcinoma diagnosis. Last author DOI 10.1038/ajg.2012.367↗
  7. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. Co-author DOI 10.1056/nejmoa1011923↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lilian Schwarz · 2 shared papers, 2018–2025 · strength 0.35
  2. Frédéric Di Fiore · 2 shared papers, 2013–2025 · strength 0.29
  3. Adrien Grancher · 1 shared paper, 2025 · strength 0.26
  4. Christophe Louvet · 1 shared paper, 2019 · strength 0.16
  5. Jean‐Baptiste Bachet · 2 shared papers, 2011–2018 · strength 0.11
  6. Déwi Vernerey · 1 shared paper, 2018 · strength 0.09
  7. Fabienne Portales · 1 shared paper, 2018 · strength 0.09
  8. António Sá Cunha · 1 shared paper, 2018 · strength 0.09
  9. Isabelle Iwanicki–Caron · 1 shared paper, 2013 · strength 0.03
  10. S. Gourgou-Bourgade · 1 shared paper, 2011 · strength 0.02
  11. Bruno Chauffert · 1 shared paper, 2011 · strength 0.02
  12. Marc Ychou · 1 shared paper, 2011 · strength 0.02
  13. Thierry Conroy · 1 shared paper, 2011 · strength 0.02
  14. Eric Assénat · 1 shared paper, 2011 · strength 0.02
  15. Christelle de la Fouchardière · 1 shared paper, 2011 · strength 0.02
  16. Michel Pierre Ducreux · 1 shared paper, 2011 · strength 0.02
  17. Antoine Adenis · 1 shared paper, 2011 · strength 0.02
  18. Jean‐Luc Raoul · 1 shared paper, 2011 · strength 0.02
  19. Olivier Bouché · 1 shared paper, 2011 · strength 0.02

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.